Psylo, a preclinical-stage biotechnology company, has partnered with the University of Sydney's Brain and Mind Centre to develop treatments for psychiatric and neurological disorders using advanced AI.
This collaboration will leverage the machine-learning behavioral analysis technology of Dr. Nick Everett, a research fellow at the University of Sydney.
This technology uses high-speed cameras and advanced data interpretation to anticipate behavior and assess the potential therapeutic properties of new drugs. Psylo will incorporate this technology to improve its drug development process.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.